# CDX2

Source: https://onco.cc/targets/cdx2/  
OnCo record `cdx2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.

## Summary

Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription. Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.33, animal model 0.66, somatic mutation 0.81). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: caudal type homeobox 2; Homeobox protein CDX-2; CDX3
- Tags: cancer-genes-wave
- Symbol: CDX2
- Class: tumor-suppressor
- Biology: Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium. Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription. Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription. Binds to and activates transcription of LPH. Activates transcription of CLDN2 and intestinal mucin MUC2. Binds to the 5'-AATTTTTTACAACACCT-3' DNA sequence in the promoter region of CA1 and activates CA1 transcription. Location: Nucleus (UniProt). Locus 13q12.2 (HGNC).
- Where found: Colorectal cancer: CIViC evidence names this disease; Oesophageal cancer: IntOGen driver in 1 cohort (ESCA); Skin cancer: Open Targets association 0.53 with skin cancer (MONDO_0002898); Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903); Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA); Melanoma: Open Targets association 0.53 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:1806: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1806
- UniProt Q99626: https://www.uniprot.org/uniprotkb/Q99626/entry
- NCBI Gene 1045: https://www.ncbi.nlm.nih.gov/gene/1045
- Ensembl ENSG00000165556: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165556

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/cdx2.json